Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00068341
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Wilshire Oncology Medical Group, Incorporated - Pomona, Pomona, California, United States
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00008086
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00010036
- Locations
- 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT00004221
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 39
- Registration Number
- NCT00066716
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Theradex
- Registration Number
- NCT00025688
- Locations
- 🇺🇸
Scott and White Clinic, Temple, Texas, United States
🇺🇸Maryland Hematology/Oncology Associates, Baltimore, Maryland, United States
🇺🇸Oncology Consultants, Houston, Texas, United States
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
- Conditions
- First Posted Date
- 2003-07-28
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- AGO Study Group
- Registration Number
- NCT00006453
- Locations
- 🇨🇦
Penticton Regional Hospital, Penticton, British Columbia, Canada
🇨🇦Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦St. Paul's Hospital - Vancouver, Vancouver, British Columbia, Canada
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 774
- Registration Number
- NCT00006229
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇦🇹AKH Vienna, Vienna (Wien), Austria
🇺🇸Memorial Hospital Cancer Center - Chattanooga, Chattanooga, Tennessee, United States
Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
- Conditions
- First Posted Date
- 2003-07-24
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT00004887
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Baptist Health South Florida
- Registration Number
- NCT00004253
- Locations
- 🇺🇸
Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Sylvester Cancer Center, University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.